scispace - formally typeset
D

Daniela Vullo

Researcher at University of Florence

Publications -  356
Citations -  15271

Daniela Vullo is an academic researcher from University of Florence. The author has contributed to research in topics: Carbonic anhydrase & Enzyme. The author has an hindex of 60, co-authored 342 publications receiving 13963 citations. Previous affiliations of Daniela Vullo include Canadian Institutes of Health Research & Griffith University.

Papers
More filters
Journal ArticleDOI

Ureido-Substituted Benzenesulfonamides Potently Inhibit Carbonic Anhydrase IX and Show Antimetastatic Activity in a Model of Breast Cancer Metastasis

TL;DR: One of them, 4-{[(3'-nitrophenyl)carbamoyl]amino}benzenesulfonamide, significantly inhibited the formation of metastases by the highly aggressive 4T1 mammary tumor cells at pharmacologic concentrations of 45 mg/kg, constituting an interesting candidate for the development of conceptually novel antimetastatic drugs.
Journal ArticleDOI

Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum—The η-carbonic anhydrases

TL;DR: The kinetic properties of PfCA for the CO2 hydration reaction, as well as an inhibition study of this enzyme with inorganic and complex anions and other molecules known to interact with zinc proteins, are demonstrated, detecting several low micromolar inhibitors.
Journal ArticleDOI

Carbonic anhydrase in the scleractinian coral stylophora pistillata: characterization, localization, and role in biomineralization

TL;DR: STPCA is a secreted form of α-CA, which possesses a CA catalytic function, similar to the secreted human CAVI, and its localization at the calicoblastic ectoderm level supports the role of STPCA in the calcification process.
Journal ArticleDOI

Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?

TL;DR: Apparently, hCA XII is a target of the antiglaucoma sulfonamides, and potent hCA XI inhibitors may be developed/used for the management of hypoxic tumors, together with inhibitors of the other tumor-associated isozyme, CA IX.
Journal ArticleDOI

Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.

TL;DR: Because CA IX is a highly active isozyme predominantly expressed in tumor tissues with poor prognosis of disease progression, this finding is very promising for the potential design of CA IX-specific inhibitors with applications as anti-tumor agents.